Summary 1
We apply transcriptome-wide RNA sequencing in postmortem autism spectrum disorder (ASD) 2 brain and controls and identify convergent alterations in the noncoding transcriptome, including primate 3 specific lncRNA, and transcript splicing in ASD cerebral cortex, but not cerebellum. We characterize an 4 attenuation of patterning between frontal and temporal cortex in ASD and identify SOX5, a transcription 5 factor involved in cortical neuron fate specification, as a likely driver of this pattern. We further show that a 6 genetically defined subtype of ASD, Duplication 15q Syndrome, shares the core transcriptomic signature of 7 idiopathic ASD, indicating that observed molecular convergence in autism brain is the likely consequence 8 of manifold genetic alterations. Using co-expression network analysis, we show that diverse forms of 9 genetic risk for ASD affect convergent, independently replicated, biological pathways and provide an 10
unprecedented resource for understanding the molecular alterations associated with ASD in humans. 11
Autism spectrum disorder (ASD) is a neurodevelopmental syndrome characterized by deficits in 1 social communication and mental flexibility 1 . Genetic risk factors contribute substantially to ASD risk, and 2 recent studies support the potential contribution of more than a thousand genes to ASD risk 2-4 . However, 3
given the shared cognitive and behavioral features across the autism spectrum, one hypothesis is that diverse 4 risk factors may converge on common molecular, cellular, and circuit level pathways to result in the shared 5 phenotype 5,6 . Analysis of the transcriptome has been used to identify common molecular pathways in the 6 cerebral cortex (CTX) from postmortem human brain tissue in individuals with ASD 7-11 . However, all 7 transcriptomic studies in ASD to date have been limited to evaluating highly expressed mRNAs 8 corresponding to protein coding genes. Moreover, most lack rigorous replication and do not assess gene 9
expression patterns across brain regions. 10 We used rRNA-depleted RNA-seq (Methods) to evaluate transcriptomes from a large set of ASD 11
and control (CTL) brain samples including neocortex (frontal and temporal) and cerebellum across 79 12 individuals (46 ASD, 33 CTL, 205 samples, Extended Data Fig. 1a -e, Supplementary Table 1 ). We first 13 compared differential gene expression (DGE) between ASD and CTL individuals in CTX from a previously 14 published 7 microarray study against new, independent gene expression profiles from RNA-seq to evaluate 15 global reproducibility of DGE in ASD. We found a high degree of replication of DGE fold changes between 16 the sample sets, despite evaluation on different gene expression platforms (fold changes at P < 0.05 in 17
previously evaluated data correlate with new data with R 2 = 0.60, Extended Data Fig. 1f ). We observed a 18 much weaker overall signal and replication in cerebellum (R 2 = 0.033, Extended Data Fig. 1g ). These 19
analyses confirm the existence of a reproducible DGE signature in ASD CTX across different platforms and 20 in independent samples. 21
We next combined samples from all individuals with idiopathic ASD into a covariate-matched 22
"ASD Discovery Set" (Extended Data Fig. 1h ) for CTX (106 samples, 26 ASD, 33 CTL individuals) and 23 held out remaining samples for replication ("ASD Replication Set", Methods). For DGE analysis, we used a 24 linear mixed effects model that accounts for biological and technical covariates (Methods) to identify 1156 25 genes differentially expressed in ASD CTX, 582 increased and 574 decreased (Benjamini-Hochberg FDR ≤ 26 0.05, Supplementary Table 2 ). Importantly, DGE analysis with additional covariates or different 27 assumptions about the distribution of the data and test statistics yielded similar results (Extended Data Fig.  28 2a). Additionally this DGE signature clusters over two-thirds of ASD samples together and this clustering is 29 not related to confounding factors such as cortical region, age, sex, and RNA quality (Figure 1a , Extended 30
Data Fig. 2b ). The most significantly down-regulated gene was PVALB (fold change = 0.53, FDR ≤ 0.05), a 31 marker for GABAergic interneurons. SST, a marker for a different subpopulation of GABAergic 32
interneurons, is also among the most downregulated (fold change = 0.61, FDR ≤ 0.05 analysis further supports the involvement of pathways implicated by these genes (Figure 1b ), confirming 38 previous findings 7 . Moreover, the upregulated set is enriched for astrocyte and microglia enriched genes, 39 and the down-regulated set is enriched for synaptic genes (Extended Data Fig. 2c ), consistent with previous 40 observations 7,11 . 41
We next sought to evaluate whether the transcriptional signature identified in the ASD Discovery Set 42
generalizes to the ASD Replication set by assessing the 1 st principal component of the DGE set, which 43
summarizes the DGE expression pattern across all cortical samples. The ASD Discovery Set and ASD 44
Replication Set share this pattern, which is significantly different for both sets compared to CTL ( Figure  1 1c). Moreover, this pattern is highly associated with ASD diagnosis, but not other biological factors, 2 technical factors, or scores on sub-domains of an ASD diagnostic tool ( Figure 1d ). These analyses 3 demonstrate that convergent differences in ASD CTX are reproducible in independent samples and are not 4 related to confounding factors. 5
We also detected 2715 lncRNAs expressed in cerebral cortex (after careful filtering for high-6
confidence transcripts, Supplementary Information), of which 62 were significantly dysregulated between 7 ASD and CTL (33 long intergenic RNAs, lincRNAs; 19 antisense transcripts; and 10 processed transcripts 8
at FDR ≤ 0.05). Similar to the protein coding genes, these transcripts' expression patterns cluster ASD and 9 CTL samples ( Figure 1e ). Most of these lncRNAs are developmentally regulated 12 , have chromatin states 10 indicative of transcription start sites (TSSs) near their 5´ end in brain 13 , and are identified in other 11 datasets 12,14 consistent with being valid, functional lncRNAs. Moreover, most (81%) exhibit primate-12 specific expression patterns in brain 15 (Supplementary Information). For example, Figure 1f depicts two 13 lincRNAs, LINC00693 and LINC00689, which are typically downregulated during development, yet are 14 upregulated in ASD CTX relative to controls (Figure 1g ), which we validated by RT-PCR (Extended Data 15 Fig. 2d ). LINC00693 sequence is present, but poorly conserved in mouse, while LINC00689 is primate-16 specific (present in macaque and other primates but not in any other species, Supplementary Information, 17
Extended Data Fig. 3 for additional examples). These data indicate that dysregulation of lncRNAs, many of 18 which are primate-specific and involved in brain development, is an important component of transcriptome 19
dysregulation observed in ASD. 20
Previous work suggested that alterations in transcript splicing may contribute to transcriptomic 21 changes in ASD 7,16,17 by evaluating splicing in a targeted manner and pooling samples across 22 individuals 7,16,17 . Given the increased sequencing depth and reduced sequencing bias across transcript length 23
in our dataset, we were able to perform an unbiased genome-wide analysis of differential alternative splicing 24 (AS). We evaluated the percent spliced in (PSI, Extended Data Fig. 4a ) for 34,025 AS events in CTX across 25 the ASD Discovery Set, encompassing skipped exons (SE), alternative 5´ splice sites (A5SS), alternative 3´ 26 splice sites (A3SS), and mutually exclusive exons (MXE) using the MATS pipeline 18 (Supplementary 27 Information). We first asked whether there was a global signal, finding significant enrichment over 28 background (Extended Data Fig. 4b ). We identified 1127 events in 833 genes at FDR ≤ 0.5 in CTX (similar 29 to the number of events at uncorrected P < 0.005). Importantly, we obtained similar results with a different 30 splice junction mapping and quantification approach (Extended Data Fig. 4c ).
31
We performed PCR validations with nine AS events from the differential splicing set (ASTN2, 32 MEF2D, ERC2, MED31, SMARCC2, SYNE1, NRCAM, GRIN1, NCAM) and found that validated changes in 33 splicing patterns were concordant with RNA-seq (Extended Data Fig. 4d -e), demonstrating that our 34 approach identifies alterations in AS with high specificity. Similar to our observations with lncRNA and 35 DGE, AS changes clustered the samples by diagnosis (Figure 2a ). The most significantly different event 36
was the inclusion of an exon in ASTN2 (ΔPSI = 5.8 indicating a mean of 5.8% difference in inclusion in 37 ASD vs CTL; P = 7.8x10 -6 ), a gene implicated by copy number variation (CNV) in ASD and other 38 developmental disorders 19 . GO term analysis of the genes implicated by these pathways indicates 39
involvement of biological processes related to neuronal projection, biological adhesion, and morphogenesis 40 (Figure 2b ), pathways where alternative isoforms are critical to specifying interactions between protein 41 products. Moreover, the 1 st principal component of the cortex differential splicing signature replicates in the 42
ASD Replication Set and is not associated with other biological or technical factors (Figures 2c-d, Extended 43
Data Fig. 5a ). Importantly, many splicing alterations occur in genes that are not differentially expressed 44 between ASD and CTL; removing AS events on genes exhibiting even nominal DGE (P < 0.05), still 1 identified a strong difference between ASD and CTL CTX (Extended Data Fig. 5b ).
2
A parallel analysis in cerebellum evaluating 32,954 AS events found no differentially regulated 3 events significant at any multiple comparison correction thresholds (Extended Data Fig. 5c , Supplementary  4  Table 3 ). There was no detectable global overlap between cerebellum and CTX above chance for events 5 significant at P < 0.05 in both comparisons (fold enrichment = 1.1, P = 0.21). This suggests that AS 6 alterations in ASD are largely confined to CTX cell types, consistent with the stronger overall DGE patterns 7 observed in CTX versus cerebellum. 8
To further explore the underlying biology of AS dysregulation, we tested whether the shared splicing 9 signature in ASD might be a product of perturbations in AS factors known to be important to neural 10 development or preferentially expressed in neural tissue. We found that the expression levels of RBFOX1, 11 RBFOX2, SRRM4, NOVA1, and PTBP1 all had high correlations (R 2 > 0.35, FDR ≤ 0.05) to AS alterations 12 in CTX (Figure 2e ), but not in cerebellum ( Figure 2f ). Furthermore, enrichment analysis revealed that most 13 changes in cortical AS occur in neuron-specific exons that are excluded in ASD (exons with ΔPSI > 50% in 14
neurons overlap with exons excluded in ASD CTX, fold enrichment = 4.1, P = 1.8x10 -7 , Extended Data Fig.  15 5d).
16
To validate a regulatory relationship between splicing factors and these events, we evaluated 17 experimental data from knockout, overexpression, and knockdown experiments for Rbfox1 20 , SRRM4 21 , 18
and PTBP1 22 , respectively . We found that exons regulated by each of these splicing factors were 19 significantly enriched in the set of exons excluded in ASD ( Figure 2g ), while in contrast, there was no 20 enrichment for targets of ESRP 23 , a splicing factor involved in epithelial cell differentiation but not 21
expressed in CTX. This shows that alterations in three splicing factors dysregulated in ASD regulate AS of 22 the neuron-specific exons whose inclusion is dysregulated in ASD in CTX and not cerebellum, indicating 23 selective alteration of neuronal splicing in ASD CTX. Remarkably, the expression patterns of these three 24
splicing factors (and others for which appropriate validation experiments were unavailable) results in 25 distinct clusters (Extended Data Fig. 5e ), suggesting that subsets of splicing factors act in different 26 individuals to mediate a common downstream AS alteration. 27
Taken together these results indicate global transcriptional alterations in ASD cerebral cortex, but 28 not cerebellum at the level of protein coding transcripts, lncRNA and AS. Therefore, to determine how these 29 different transcriptomic subcategories relate to each other in ASD, we compared the 1 st PC for each type of 30 transcriptomic alteration across individuals ( Figure 2h ). Remarkably, the PCs are highly correlated (R 2 > 31 0.8) indicating that the transcriptomic alteration is a unitary phenomenon across protein coding, noncoding, 32 and splicing levels, rather than distinct forms of molecular alteration. 33
Previous analysis with gene expression microarrays in a small cohort suggested that the typical 34 pattern of transcriptional differences between the frontal and temporal cortex may be attenuated in ASD 7 .
35
To further test this possibility, we evaluated DGE between CTX regions (Supplementary Information) in 16 36 matched frontal and temporal CTX sample pairs from ASD and CTL subjects and found 551 genes 37 differentially expressed between regions in controls, but only 51 in ASD (FDR ≤ 0.05; Figure 3a ). We refer 38 to the set of 523 genes with this pattern in CTL, but not ASD as the "Attenuated Cortical Patterning" set. 39
The attenuation of patterning is evident from the global distribution of test statistics between frontal and 40 temporal CTX in ASD and CTL and genes in this set do not show a greater difference in variability in ASD 41 versus controls compared to other genes (Kolmogorov-Smirnov test, two-tailed P = 0.11, Extended Data 42 Fig. 6a ). 43
We complemented this analysis with a machine learning approach using all 123 cortical samples, 1
training a regularized regression model 24 to classify frontal versus temporal CTX with independent gene 2 expression data from BrainSpan 25 (Extended Data Fig. 6b , Supplementary Information). Multiple 3 approaches to training the classifier with BrainSpan can differentiate between frontal and temporal CTX in 4 both CTL and ASD (Extended Data Fig. 6c -e), demonstrating that dissection and sample quality in our 5 samples are of high quality. Loss of classification accuracy in ASD compared to CTL was observed when 6 restricting the model to the genes with the most attenuated patterning in ASD (Extended Data Fig. 6f ), 7
demonstrating that attenuation of patterning generalizes across all samples. The Attenuated Cortical 8
Patterning set includes multiple genes known to be involved in cell-cell communication and cortical 9
patterning, such as PCDH10, PCDH17, CDH12, MET, and PDGFD, which was recently shown to mediate 10 human specific aspects of cerebral cortical development 26 . GO term enrichment analysis of the Attenuated 11
Cortical Patterning set identified enrichment for G protein coupled signaling, Wnt receptor signaling, and 12 calcium binding, among several developmental processes ( Figure 3b ), and cell type enrichment analysis did 13 not identify a strong preference for a particular cell type (Extended Data Fig. 6g ). 14 To identify potential drivers of the alteration in cortical patterning, we evaluated transcription factor 15 binding site enrichment upstream of genes in the Attenuated Cortical Patterning set (Supplementary 16
Information), and found an enrichment of SOX5 binding motifs (upstream of 364/523 genes, Figure 3c ). 17
Remarkably, SOX5 itself belongs to the Attenuated Cortical Patterning set: while SOX5 is differentially 18 expressed between frontal and temporal CTX in CTL, it is not in ASD ( Figure 3d ). We thus predicted that if 19
SOX5 regulates cortically patterned genes, its expression should correlate with target gene transcript levels. 20
Consistent with this prediction, we found that genes in the Attenuated Cortical Patterning set are anti-21 correlated with SOX5 in CTL CTX, but not in ASD CTX (Figure 3e , top left; Wilcoxon rank sum test of R 22 values, P = 0.01), suggesting that the normal role of SOX5 as a transcriptional repressor may be disrupted in 23
ASD. We reasoned that a true loss of SOX5-mediated cortical patterning would be specific to the predicted 24 SOX5 targets. Consistent with this, we find a loss of correlations between SOX5 and predicted targets, but 25 no difference in correlations between SOX5 and non-targets in the Attenuated Cortical Patterning set ( Figure  26 3e). Taken together, these findings show that a loss of regional patterning downstream of the transcriptional 27
repressor SOX5, which plays a crucial role in glutamatergic neuron development 27,28 , contributes to the loss 28 of regional identity in ASD.
29
Gene expression changes in postmortem brain may be a consequence of genetic factors, 30 environmental factors, or both. Brain tissue from individuals with ASD that harbor known, penetrant genetic 31 causes are very rare. However, we were able to identify postmortem brain tissue from 8 subjects with one of 32 the more common recurrent forms of ASD, Duplication 15q Syndrome (dup15q, which is present in about 33 0.5-1% of ASD cases, see Extended Data Fig. 7a for characterization of duplications). We performed RNA-34
seq across frontal and temporal cortex and compared DGE changes in dup15q with those observed in 35 individuals with idiopathic ASD to better understand the extent to which the observed molecular pathology 36
overlaps. As expected, most genes in the 15q11.1-13.2 duplicated region have higher expression in dup15q 37 CTX compared to CTL (Figure 4a ), although SNRPN and SNURF were notably downregulated. Conversely, 38 no significant upregulation of genes in this region were identified in idiopathic ASD or controls. Strikingly, 39
when we assessed genome-wide expression changes, we observed a strong signal of DGE in dup15q that 40
widely overlaps with that of idiopathic ASD (fold changes at FDR ≤ 0.05 in dup15q correlate with 41 idiopathic ASD with R 2 = 0.79, Figure 4b ). Moreover, the slope of the best-fit line through these changes is 42
2.0, indicating that on average, the transcriptional changes in dup15q CTX are highly similar, but twice the 43 magnitude of those observed in ASD CTX. 44
Next, we sought to evaluate AS changes in dup15q. There is only one significant splicing change in 1 the dup15q region ( Supplementary Table 3 ), consistent with the idea that duplication in this region 2 duplicates all isoforms of the genes, resulting in minimal alteration of transcript structure. Similar to DGE, 3 global AS analysis in dup15q CTX vs to CTL CTX revealed a stronger, but highly overlapping signature 4
with idiopathic ASD CTX (fold changes at FDR ≤ 0.2 in dup15q agree correlate with idiopathic ASD with 5 R 2 = 0.66) indicating that splicing changes in dup15q syndrome recapitulate those of idiopathic ASD 6 ( Figure 4c ). The slope of the best-fit line through the PSI for spliced exons in dup15q CTX compared to 7 those in ASD CTX is 2.5 similar to DGE. Notably, both gene expression and AS changes in dup15q 8 implicated similar pathways as those found in idiopathic ASD (Extended Data Fig. 7c-d ). Clustering dup15q 9
samples and CTL samples using both the DGE set and the differential AS set showed that all dup15q 10 samples cluster together (Figure 4d ), as opposed to the more variable clustering of idiopathic ASD, 11
supporting the hypothesis that this shared genetic abnormality leads to a more homogeneous molecular 12
phenotype. 13
Next, to test whether this molecular ASD signature may be due to independent of postmortem or 14 reactive effects (Supplementary Information), we compared our data with gene expression profiles from a 15 iPSC-derived neurons (nIPSCs) 29 from dup15q were available, we could use these data to definitively reveal 16
which changes in dup15q CTX are independent of postmortem or reactive effects (Supplementary 17
Information), since such effects are not present in vitro. We observe that DGE in the 15q region is 18
concordant with that seen in the nIPSCs (Figure 4e ), even though the sample size is small and the analysis is 19
likely underpowered. Upregulated changes in dup15q are also seen in nIPSCs (Figure 4f ), consistent with 20 our other statistical analyses showing limited effects of potential confounders. The very immature, fetal state 21 of the nIPSCs 30 likely explains the absence of an enrichment signal for genes downregulated in postnatal 22 ASD brain, which are enriched for genes involved in neurons with more mature synapses. 23
We next applied gene network analysis to construct an organizing framework to understand shared 24 biological functions across idiopathic ASD and dup15q (combining the ASD Discovery Set, ASD 25
Replication Set, and dup15q set). We utilized Weighted Gene Co-expression Network Analysis (WGCNA), 26
which identifies groups of genes with shared expression patterns across samples (modules) from which 27 shared biological function is inferred. Modules identified via WGCNA can than be related to a range of 28 relevant phenotypes and potential confounders 31,32 . We applied signed co-expression analysis and used 29
bootstrapping to ensure the network was robust, and not dependent on any subset of samples 30 (Supplementary Information), while controlling for technical factors and RNA quality ("Adjusted FPKM" 31 levels, Methods). WGCNA identified 16 co-expression modules (Extended Data Fig. 8a , Supplementary  32  Table 2 ), which are further characterized by their association to ASD (Extended Data Fig. 8b ), enrichment 33 for cell-type specific genes (Extended Data Fig. 8c ), and enrichment for GO terms (Extended Data Fig. 9 ).
34
Of the downregulated modules, three are associated with ASD and dup15q (M1/10/17) and one with dup15q 35 only (M11). Five of the upregulated modules are associated with ASD and dup15q (M4/5/6/9/12) and one is 36 specific to dup15q (M13) (Figure 5a, top) . Additionally, we identified a module strongly enriched for genes 37 from the Attenuated Cortical Patterning set and Wnt signaling that contains SOX5 (M12; fold enrichment = 38
3.0, P = 3x10 -8 ), verifying the strong relationship observed between the Wnt pathway regulating TF SOX5 39 and attenuation of cortical patterning 33 . 40
Notably, the modules identified here significantly overlap with previous patterns identified in ASD 41
(asdM12 array and asdM16 array 7 ; Figure 5a , middle). We found that the ASD-associated modules identified by 42
our larger sample size and RNA-seq provide significant refinement of previous observations by identifying 43 more discrete biological processes related to cortical development 34 , the post-synaptic density 35 , and 44 lncRNAs (Figure 5a, bottom) . For example, M1 overlaps a subset of asdM12 array (fold enrichment = 5.7) 1 and developmental modules (devM16 fold enrichment = 3.7), and is enriched for proteins found in the PSD 2 and genes involved in calcium signaling and gated ion channel signaling. Another subset of asdM12 array , 3 M10 (fold enrichment = 11) overlaps more with a mid-fetal upregulated cortical development module 4 (devM13 fold enrichment = 4.0), and genes involved in secretory pathways and intracellular signaling. A 5 third module, M17 shows the least overlap with asdM12 array (fold enrichment = 2.2) and is related to energy 6 metabolism. Notably, these three modules are enriched for neuron-specific genes (Extended Data Fig. 8c) , 7
but not all neuronal modules are down regulated in ASD (M3 is not altered in ASD CTX). Taken together, 8 specific neurobiological processes are affected in individuals with ASD related to developmentally 9 regulated neurodevelopmental processes. 10
The most upregulated modules, M5 and M9, both strongly overlap (fold enrichments > 20) with 11 previously identified upregulated co-expression module asdM16 array . M5 is enriched for microglial cell 12 markers and immune response pathways, whereas M9 is enriched for astrocyte markers and immune-13 mediated signaling and immune cell activation (Extended Data Fig. 8c , Extended Data Fig. 9 ). This analysis 14
clearly separates the contributions of the coordinated biological processes of microglial activation and 15
reactive astrocytosis, which were previously not distinguishable as separate modules 7 . Thus, our analysis 16
pinpoints more specific biological pathways in idiopathic ASD than those previously identified and reveals 17 that similar changes occur downstream of the genetic perturbation in dup15q.
18
We evaluated the relationship between the five modules most strongly associated with ASD 19
(M1/5/9/10/17, which are supported by module-trait association analysis and gene set enrichment analysis, 20
Supplementary Information), and found that there was a remarkably high anti-correlation between the 21 eigengene of M5 and downregulated modules, particularly M1 (R 2 = 0.76) ( Figure 5b ). M1 (Figure 5c ) is 22 downregulated in ASD and enriched for genes at the PSD and genes involved in synaptic transmission, 23
while M5 (Figure 5d ) is enriched for microglial genes and cytokine activation. This strong anti-correlation 24
between microglial signaling and synaptic signaling in ASD and dup15q provides evidence in humans for 25 dysregulation of microglia-mediated synaptic pruning, as previously suggested 36 . 26
Next, to determine the role of causal genetic variation, we evaluated enrichment of both rare genetic 27 variants, focusing on genes affected by ASD associated gene disrupting (LGD) de novo mutations 37 , and 28 common variants 38, 39 . Genes within three modules, M1, M3, and M12, show enrichment for common 29 variation signal for ASD (Figure 5e , Methods). Remarkably, M12 (Figure 5f ), which is related to cortical 30 patterning and Wnt signaling, also exhibit GWAS signal enrichment, providing the first evidence that risk 31 conferred by common variation in ASD may affect regionalization of the cortex. Interestingly, M3 is 32 significantly enriched for both schizophrenia (SCZ) and ASD common variants, is related to synaptic 33 transmission, nervous system development, and regulation of ion channel activity (Extended Data Fig. 9 ), 34
consistent with the notion that ASD and SCZ share common and rare genetic risk 1,40-43 . 35 We only identified one module, M2 (Figure 5g ), as significantly enriched in protein disrupting 36
(nonsense, splice site, or frameshift) rare de novo variants previously associated with SCZ and ASD. M2 37 overlaps with a cortical developmental module implicated in ASD 34 (devM2 fold enrichment = 5.1).
38
Notably, M2 is not differential between ASD and CTL in our dataset, consistent with the observation that 39
these genes are primarily expressed during early neuronal development in fetal brain 34 . Remarkably, M2 40
contains an unusually large fraction of lncRNAs (15% of the genes in M2 are classified as lncRNAs, while 41 other modules are 1-5% lncRNA). We hypothesize that, in addition to protein coding genes involved in 42
transcriptional and chromatin regulation, rare de novo variants may also affect lncRNAs in ASD, a 43 prediction that will be testable once large sets of whole genome sequences are available. 44
These combined transcriptomic and genetic analyses reveal that different forms of genetic variation 1 affect biological processes involved in multiple stages of cortical development. Common genetic risk is 2 enriched in M3, M1, and M12, which reflect early glutamatergic neurogenesis, later neuronal function, and 3 cortical patterning, respectively. We also observe that rare de novo variation, which is enriched in M2, 4 affects distinct biology related to transcriptional regulation and chromatin modification. These findings are 5 consistent with transcriptomic analyses of early prenatal brain development and ASD risk mutations that 6
implicate chromatin regulation and glutamatergic neuron development 34, 44 . 7
We provide the first comprehensive picture of largely unexplored aspects of transcription in ASD, 8
lncRNA and alternative splicing, and identify a strong convergent signal in these, as well as protein coding 9 genes 7 . These results will aid in interpreting genetic variation outside of the known exome, as whole 10 genome sequencing supplants current methods. A role of lncRNAs has been previously explored in ASD 45 , 11 but only two individuals were evaluated with targeted microarrays. We evaluate lncRNAs in an unbiased 12 manner across many individuals, notably identifying an enrichment of lncRNAs in M2, most of which are 13 uncharacterized in brain and arose on the primate lineage. The involvement of lncRNAs in this early 14 developmental program that is enriched for de novo mutations implicated in ASD suggests their study will 15 be particularly relevant to understanding the emergence of primate higher cognition on the mammalian 16 lineage, and by extension human brain evolution 15,46,47 . 17
We also provide the first confirmation of an attenuation of genes that typically show differential 18 expression between frontal and temporal lobe in ASD CTX and further identified SOX5, known to regulate 19 cortical laminar development 50, 51 , as a putative regulator of this disruption. That M12, which is enriched for 20 genes exhibiting cortical regionalization and is also enriched in ASD GWAS signal, supports the prediction 21 that attenuation of patterning may be mediated by common genetic variation in or near the SOX5 target 22
genes. Disruption of cortical lamination by direct effects on glutamatergic neurogenesis and function has 23 been predicted by independent data, including network analyses of rare ASD associated variants identified 24
in exome sequencing studies 34, 44 . 25
These data, in conjunction with previous studies, reveal a consistent picture of the ASD's emerging 26 postnatal and adult pathology. Specific neuronal signaling and synaptic molecules are downregulated and 27 astrocyte and microglial genes are upregulated in over 2/3 of cases. Microglial infiltration has been observed 28 in ASD cortex with independent methods 52 , and normal microglial pruning has been shown to be necessary 29 for brain development 36 . Our findings further suggest that aberrant microglial-neuronal interactions may be 30 pervasive in ASD and related to the gene expression signature seen in a majority of individuals. In our 31
comprehensive AS analysis, we identify three splicing factors upstream of the altered splicing signature 32 observed in ASD CTX. These factors are known to be involved in coordinating sequential processes in 33 neuronal development 17,21 and maintaining neuronal function 48, 49 . It may therefore be sufficient to disrupt 34
any one of these factors to induce a similar outcome during brain development, which would be consistent 35 with the shared downstream perturbation observed here. 36
Finally, evaluation of the transcriptome in dup15q supports the enormous value of the "genotype 37
first" approach of studying syndromic forms of ASD, with known penetrant genetic lesions 53 . It is highly 38
unlikely that the shared transcriptional dysregulation in dup15q is due to a shared environmental insult. 39
Thus, the most parsimonious explanation for the convergent transcriptomic pathology seen in all dup15q 40 and over 2/3 of the cases of idiopathic ASD is that it represents an adaptive or maladaptive response to a 41 primary genetic insult, which in most cases of ASD will be genetic 2,54 . As future investigations pursue the 42 full range of causal genetic variation contributing to ASD risk, these analyses and data will be valuable for 43
interpreting genetic and epigenetic studies of ASD as well as those of other neuropsychiatric disorders. 44 genome-wide whole-exome sequencing data (Rare de novo hit genes) and genome-wide association study 9
Figures & Figure Legends
(GWAS) results in ASD, schizophrenia (SCZ), and intellectual disability (ID). Boxes are filled if the odds 10 ratio is greater than 0, and the enrichment P < 0.05. Asterisks* indicate FDR ≤ 0.05 across all comparisons 1 in a and e. f,g, similar to c, but for M12 and M2, respectively. Abbreviations: LGD, likely gene disrupting, 2 genes affected by nonsense, nonsynonymous, or splice-site mutations or frame-shift indels; AGRE, 3 AGP/CHOP, and PGC refer to consortia that collect genetic data (Supplementary Information for details). 4 5
Methods

7
Sample description: Brain tissue for ASD and control individuals was acquired from the Autism Tissue 8
Program (ATP) brain bank at the Harvard Brain and Tissue Bank and the University of Maryland Brain and 9
Tissue Bank (a Brain and Tissue Repository of the NIH NeuroBioBank). Sample acquisition protocols were 10 followed for each brain bank, and samples were de-identified prior to acquisition. Brain sample and 11
individual level metadata is available in Supplementary Table 1 . 12 13
RNA-seq methodology: Starting with 1ug of total RNA, samples were rRNA depleted (RiboZero Gold, 14
Illumina) and libraries were prepared using the TruSeq v2 kit (Illumina) to construct unstranded libraries 15
with a mean fragment size of 150bp (range 100-300bp) that underwent 50bp paired end sequencing on an 16
Illumina HiSeq 2000 or 2500 machine. Paired-end reads were mapped to hg19 using Gencode v18 17 annotations 55 via Tophat2 56 . Gene expression levels were quantified using union exon models with 18
HTSeq 57 . For additional and information on sequencing and read alignment parameters, please see 19
Supplementary Information. 20 21
Sample sets for analysis: For differential gene expression and splicing analysis, we defined an age matched 22
set, referred to as the ASD Discovery Set (106 samples in CTX, 51 in cerebellum) of idiopathic ASD and 23 control samples for the discovery set, and held out younger or unmatched samples as the ASD Discovery 24
Set (17 in CTX, 8 in cerebellum). Dup15q individuals were analysed separately, utilizing the full set of 25 controls from the ASD Discovery Set. For co-expression network analysis, we combined the discovery set, 26
replication set, and dup15q individuals for a total of 137 CTX samples and 59 cerebellum samples.
28
Differential Gene Expression (DGE): DGE analysis was performed with expression levels adjusted for gene 29 length, library size, and G+C content (referred to as "Normalized FPKM") Supplementary Information. 30
CTX samples (frontal and temporal) were analyzed separately from cerebellum samples. A linear mixed 31 effects model framework was used to assess differential expression in log2(Normalized FPKM) values for 32 each gene for cortical regions (as multiple brain regions were available from the same individuals) and a 33
linear model was used for cerebellum (where one brain region was available in each individual, with a 34
handful of technical replicates removed). Individual brain ID was treated as a random effect, while age, sex, 35
brain region (except in the case of cerebellum, where there is only one region), and diagnoses were treated 36 as fixed effects. We also used technical covariates accounting for RNA quality, library preparation, and 37 batch effects as fixed effects into this model (Supplementary Information). 38 39
Reproducibility analyses: We assessed replication between datasets by evaluating the concordance between 40 independent sample sets by comparing the squared correlation (R 2 ) of fold changes of genes in each sample 41 set at a non-stringent P value threshold. This general approach has been shown to be effective for 42
identifying reproducible gene expression patterns 58 , and we modify it such that the P value threshold is set 43
in one sample set (the x axis in the scatterplots), and the R 2 with fold changes in these genes are evaluated in 44
an independent sample set (the y axis in the scatterplots).
46
Differential Splicing Analysis: Alternative splicing was quantified using the percent spliced in (PSI) metric 47
using Multivariate Analysis of Transcript Splicing (MATS, v3.08) 18 . For each event, MATS reports counts 48
supporting the inclusion (I) or exclusion (E) of a splicing event. To reduce spurious events due to low 49 counts, we required at least 80% of samples to have I + S >= 10. For these events, the percent spliced in is 1 calculated as PSI = I / (I + S) (Extended Data Fig. 4a ). Statistical analysis for differential splicing was 2 performed utilizing the linear mixed effects model regression framework as described above for DGE. This 3 approach is advantageous over existing methods as it allows modeling of covariates and takes into 4 consideration the variability in PSI across samples when assessing event significance with ASD 5 (Supplementary Information). 6 7
Genotyping dup15q: For Dup15q samples, the type of duplication and copy number in the breakpoint 2-3 8 region were available for these brains 59 . To expand this to the regions between each of the recurrent 9 breakpoint in these samples, 7/8 dup15q brains were genotyped (one was not genotyped due to limitations in 10 tissue availability). The number of copies between each of the breakpoints is reported in Extended Data Fig.  11 7a. 12 13
Co-expression network analysis: The R package weighted gene co-expression network analysis (WGCNA) 14 was used to construct co-expression networks using the technical variation normalized data 31,60 (referred to 15
as "Adjusted FPKM"). We used the biweight midcorrelation to assess correlations between 16 log2(Normalized FPKM) and parameters for network analysis are described in Supplementary Information. 17
Notably, we utilized a modified version of WGCNA that involves bootstrapping the underlying dataset 100 18 times and constructing 100 networks. The consensus of these networks (50 th percentile across all edges) was 19 then used as the final network 32 , ensuring that a handful of samples do not determine the network structure. 20
For module-trait analyses, 1 st principal component of each module (eigengene) was related to ASD 21 diagnosis, age, sex, and brain region in a linear mixed effects framework as above, only replacing the 22 expression values of each gene with the eigengene. 23 24
Enrichment analysis of gene sets and GWAS: Enrichment analyses were performed either with Fisher's 25 exact test (cell type and splicing factor enrichments) or logistic regression (all enrichment analyses in Figure  26 5). We used logistic regression in the latter case to control for gene length or other biases that may influence 27 enrichment analysis (Supplementary Information). All GO term enrichment analysis was performed using 28
GO Elite 61 with 10,000 permutations. We focused on molecular function and biological process terms for 29 display purposes. Extended Data Figure 1 | Methodology, quality control, and differential expression replication analysis. a, 2
RNA-seq workflow, including RNA extraction, library preparation, sequencing, read alignment, and quality 3 control. b, RNA-seq quality and alignment statistics from this study, including RNA integrity number 4 (RIN), number of aligned reads, proportion of reads mapping to different genomic features (mRNA, 5 intronic, intergenic), and bias in coverage from the 5' to the 3' end of the top 1000 expressed transcripts 6 (statistics compiled using PicardTools). c, Similar statistics as in b for another RNA-seq study that utilized 7
polyA tail selection mRNA-seq to evaluate the transcriptome in ASD cortex 11 (primarily BA19, visual 8
cortex, but also including some BA10/44 samples, frontal cortex). d, RNA-seq read coverage relative to 9 normalized gene length across transcripts from the 5' to the 3' end in this study. e, Dependence between 10 coverage and RIN across gene body (correlation between RIN and coverage in d across samples). f, 11
Correlation of ASD vs CTL fold changes between previously evaluated and new ASD samples in CTX by 12 microarray (left) and RNA-seq (right) using genes that were at P < 0.05 the samples from Voineagu et al., 13 2011. g, Correlation between effect sizes as in f, but for cerebellum (CB) samples. h,i, Correlation between 1 covariates and ASD vs CTL status in CTX (h) and CB (i) in the ASD Discovery Set. 2 3 4
Extended Data Figure 2 | Transcriptome-wide differential gene expression (DGE) analysis in CTX. a, 5
Comparison of P value rankings across different methods for DGE with Spearman's correlation. From left 6
to right: removal of three additional principal components of sequencing statistics (Supplementary 7
Information) related to RNA-sequencing quality, application of a permutation analysis for DGE P value 8 computation, application of variance-weighted linear regression for DGE 62 , and using surrogate variable 9 analysis for DGE 63 CTL in CTX for all events (left) and event subtypes (SE, spiced exon; A5SS, alternative 5' splice site; 4 A3SS, alternative 3' splice site; MXE, mutually exclusive exons). c, Comparison of the CTX splicing 5 analyses in when using PSI values obtained via read alignment by TopHat2 64 followed by the MATS 18 1 pipeline (used throughout this study) against read alignment by OLego followed by Quantas 65 . d, 2
Comparison of ΔPSI values in nine splicing events between PCR and RNA-seq. e, PCR validation and 3 sashimi plots for the nine splicing events delineated in d, from the samples highlighted in Extended Data 4 Fig. 5a . region. Genome-wide CNV analysis allowed evaluation of copy number in additional regions from previous 3 studies 59,66 . b, Differential expression across the 15q region of interest in dup15q vs CTL and ASD vs CTL 1 cerebellum, note only 3 samples were available for dup15q cerebellum so additional analyses were not 2 pursued. c, Gene Ontology term enrichment analysis for the dup15q CTX differential expression set. d, 3
Gene Ontology term enrichment analysis for the dup15q CTX differential splicing (DS) set. e, Hierarchical 4 clustering of iPSC-derived neurons from dup15q, Angelman syndrome, and a control 29 . 5 6 7
Extended Data Figure 8 | Co-expression network analysis in ASD CTX. a, Modules identified from a 8 dendrogram constructed from a consensus of 100 bootstrapped datasets using the 137 CTX samples. 9
Correlations for each gene to each measured factor are delineated below the dendrogram (blue = negative, 10 red = positive correlation). b, Module-trait associations as computed by a linear mixed effects model with all 11 factors on the x-axis used as covariates. All P values are displayed where the coefficient passed p < 0.01. 12
Note that this alternative approach to module-trait association agrees with the Fisher's exact test used in 13 Figure 5a when the fold enrichment for module overlap with DGE sets is > 2.8, and we use an intersection 14 of both methods for the modules focused on in Figure 5b . c, Module enrichments for cell type specific gene 1 expression patterns. None. 43
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